Teva Pharmaceutical Industries Limited · SWB:TEV

Teva Pharmaceutical Industries Limited financial statements

Teva Pharmaceutical Industries Limited's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue17.3B16.5B15.8B14.9B15.9B16.7B16.9B18.3B21.9B21.9B
Cost of revenue8.32B8.48B8.20B7.95B8.28B8.93B9.35B9.97B11.2B10.3B
Gross profit8.94B8.06B7.64B6.97B7.59B7.73B7.54B8.30B10.6B11.7B
Research and development1.01B998.0M953.0M98.0M967.0M997.0M1.01B114.0M175.0M422.0M
Selling, general and administrative1.29B1.16B1.16B1.18B1.10B1.17B1.19B1.30B1.33B1.24B
Operating income2.16B-303.0M433.0M-2.20B1.72B-3.57B-443.0M-1.64B-17.5B2.15B
Depreciation and amortization1.00B1.06B1.15B1.31B1.33B1.56B1.72B1.84B2.11B1.52B
EBITDA3.16B756.0M1.59B-889.0M3.05B-2.02B1.28B205.0M-15.4B3.68B
Interest expense916.0M1.00B1.03B930.0M891.0M901.0M822.0M920.0M875.0M546.0M
Income before tax1.22B-1.28B-624.0M-3.16B658.0M-4.41B-1.26B-2.60B-18.4B824.0M
Income tax-180.0M676.0M-7.00M-643.0M211.0M-168.0M-278.0M-195.0M-1.93B521.0M
Net income1.41B-1.64B-559.0M-2.45B417.0M-3.99B-999.0M-2.15B-16.3B329.0M
Earnings per share, basic1.23-1.45-0.50-2.200.38-3.64-0.91-2.35-16.260.07
Earnings per share, diluted1.21-1.45-0.50-2.200.38-3.64-0.91-2.35-16.260.07

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents3.56B3.30B3.23B2.80B2.17B2.18B1.98B1.78B963.0M988.0M
Short-term investments2.00M14.0M679.0M
Receivables3.71B3.06B3.41B3.70B4.53B4.58B5.68B5.82B7.13B7.52B
Inventory3.18B3.01B4.02B3.83B3.82B4.40B4.42B4.73B4.92B4.95B
Current assets13.9B12.6B12.5B12.1B12.6B13.0B13.5B13.8B15.4B17.2B
Property, plant and equipment4.08B4.58B5.75B5.74B5.98B6.30B6.44B6.87B7.67B8.07B
Goodwill16.0B16.0B17.2B17.2B17.6B20.6B24.8B24.9B28.4B44.4B
Total assets40.7B39.3B43.5B44.0B47.7B50.6B57.5B60.7B70.6B93.1B
Accounts payable225.0M158.0M108.0M1.89B1.69B1.76B1.72B1.85B2.07B2.16B
Current liabilities13.5B12.8B12.2B11.5B11.0B13.2B13.7B14.3B17.9B18.5B
Long-term debt15.0B16.0B18.2B19.1B21.6B22.7B24.6B26.7B28.8B32.5B
Total debt1.80B1.76B1.65B2.09B1.40B2.67B1.83B1.70B28.8B32.5B
Total liabilities32.8B33.6B35.4B35.4B36.4B39.6B42.4B44.9B51.9B58.1B
Shareholders' equity7.91B5.37B7.51B7.80B10.3B10.0B14.0B14.7B17.4B33.3B
Shares outstanding1.17B1.17B1.15B1.15B1.13B1.11B1.10B1.10B1.09B1.09B

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations1.65B1.25B1.37B1.59B798.0M1.22B748.0M2.45B2.23B3.89B
Capital spending-501.0M-498.0M-526.0M-548.0M-562.0M-578.0M-525.0M-651.0M-874.0M-901.0M
Free cash flow1.15B749.0M842.0M1.04B236.0M638.0M223.0M1.79B1.35B2.99B
Cash from investing737.0M792.0M968.0M656.0M1.52B863.0M1.35B1.87B3.45B-34.4B
Cash from financing-2.15B-1.79B-1.91B-1.49B-2.17B-1.89B-1.93B-3.35B-5.75B25.2B
Dividends paid-52.0M-12.0M-901.0M-1.30B
Share buybacks00
Change in cash256.0M74.0M393.0M636.0M21.0M202.0M193.0M819.0M-25.0M-5.96B